Table 2.

Association of adiponectin and c-peptide levels with prostate cancer in CPS-II

All aggressiveaHigh riskb
AnalyteCasesControlsOR (95% CI)CasesControlsOR (95% CI)
Adiponectin (ng/mL)
 <6,17862681.00 (ref)43381.00 (ref)
 6,178–<7,87961681.05 (0.62–1.78)38430.76 (0.38–1.52)
 7,879–<11,10986681.43 (0.87–2.36)55431.10 (0.58–2.11)
 ≥11,10963681.11 (0.64–1.93)36480.70 (0.33–1.49)
  P trend0.590.56
c-peptide (ng/mL)
 <2.9572681.00 (ref)43471.00 (ref)
 2.95–<4.6959680.69 (0.42–1.16)34410.94 (0.48–1.82)
 4.69–<6.5560680.77 (0.47–1.28)39420.95 (0.48–1.87)
 ≥6.5580671.18 (0.69–2.02)55411.41 (0.72–2.78)
  P trend0.440.31

NOTE: Model stratified on pairs and adjusted for family history of prostate cancer, body mass index, physical activity in metabolic equivalents (METs), total calcium intake, and energy intake.

  • aGleason score ≥7 (4+3) or T3 or T4 or death from prostate cancer.

  • bGleason score ≥8 or stage T3 or T4.